For example, we developed custom algorithms for the indications for PSMA PET/CT imaging in de novo and recurrent prostate cancerand pathways for management (Figure 3) that sites could modify to their institutional practices and post for other clinical colleagues who may not be as well-versed in prostate cancer management. This evidence concerns the gene FOLH1 and Familial prostate cancer.